(6-methyl-2-imidazo[1,2-a]pyridin-3-yl)acetamide | 722539-17-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: (6-methyl-2-imidazo[1,2-a]pyridin-3-yl)acetamide
• 英文别名: 2-(6-Methylimidazo[1,2-a]pyridin-3-yl)acetamide
• CAS: 722539-17-5
• 化学式: C₁₀H₁₁N₃O
• 分子量: 189.217
• InChiKey: XUZMDHALDVYKAY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  60.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (6-methyl-2-imidazo[1,2-a]pyridin-3-yl)acetamide 在 盐酸 、 potassium tert-butylate 、 三乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 二氯甲烷 为溶剂， 生成 3-(6-Methylimidazo[1,2-a]pyridin-3-yl)-4-[10-(piperidine-1-carbonyl)-1,10-diazatricyclo[6.4.1.04,13]trideca-2,4,6,8(13)-tetraen-3-yl]pyrrole-2,5-dione
  参考文献：
  名称：

  Substituted 3-Imidazo[1,2-a]pyridin-3-yl- 4-(1,2,3,4-tetrahydro-[1,4]diazepino- [6,7,1-hi]indol-7-yl)pyrrole-2,5-diones as Highly Selective and Potent Inhibitors of Glycogen Synthase Kinase-3

  摘要：

  Glycogen synthase kinase-3 (GSK3) is involved in signaling from the insulin receptor. Inhibitors of GSK3 are expected to effect lowering of plasma glucose similar to insulin, making GSK3 an attractive target for the treatment of type 2 diabetes. Herein we report the discovery of a series of potent and selective GSK3 inhibitors. Compounds 7-12 show oral activity in an in vivo model of type II diabetes, and 9 and 12 have desirable PK properties.

  DOI：

  10.1021/jm049768a
• 作为产物：
  描述：

  2-氨基-5-甲基吡啶 在 氨 、 对甲苯磺酸 作用下， 以 甲醇 、 乙腈 为溶剂， 反应 4.0h， 生成 (6-methyl-2-imidazo[1,2-a]pyridin-3-yl)acetamide
  参考文献：
  名称：

  Substituted 3-Imidazo[1,2-a]pyridin-3-yl- 4-(1,2,3,4-tetrahydro-[1,4]diazepino- [6,7,1-hi]indol-7-yl)pyrrole-2,5-diones as Highly Selective and Potent Inhibitors of Glycogen Synthase Kinase-3

  摘要：

  Glycogen synthase kinase-3 (GSK3) is involved in signaling from the insulin receptor. Inhibitors of GSK3 are expected to effect lowering of plasma glucose similar to insulin, making GSK3 an attractive target for the treatment of type 2 diabetes. Herein we report the discovery of a series of potent and selective GSK3 inhibitors. Compounds 7-12 show oral activity in an in vivo model of type II diabetes, and 9 and 12 have desirable PK properties.

  DOI：

  10.1021/jm049768a

文献信息

• Substituted 3-Imidazo[1,2-<i>a</i>]pyridin-3-yl- 4-(1,2,3,4-tetrahydro-[1,4]diazepino- [6,7,1-<i>hi</i>]indol-7-yl)pyrrole-2,5-diones as Highly Selective and Potent Inhibitors of Glycogen Synthase Kinase-3
  作者：Thomas A. Engler、James R. Henry、Sushant Malhotra、Brian Cunningham、Kelly Furness、Joseph Brozinick、Timothy P. Burkholder、Michael P. Clay、Joshua Clayton、Clive Diefenbacher、Eric Hawkins、Philip W. Iversen、Yihong Li、Terry D. Lindstrom、Angela L. Marquart、Johnathan McLean、David Mendel、Elizabeth Misener、Daniel Briere、John C. O'Toole、Warren J. Porter、Steven Queener、Jon K. Reel、Rebecca A. Owens、Richard A. Brier、Thomas E. Eessalu、Jill R. Wagner、Robert M. Campbell、Renee Vaughn

  DOI：10.1021/jm049768a

  日期：2004.7.1

  Glycogen synthase kinase-3 (GSK3) is involved in signaling from the insulin receptor. Inhibitors of GSK3 are expected to effect lowering of plasma glucose similar to insulin, making GSK3 an attractive target for the treatment of type 2 diabetes. Herein we report the discovery of a series of potent and selective GSK3 inhibitors. Compounds 7-12 show oral activity in an in vivo model of type II diabetes, and 9 and 12 have desirable PK properties.